Previous close | 22.90 |
Open | 11.77 |
Bid | 11.45 |
Ask | 12.85 |
Strike | 65.00 |
Expiry date | 2025-03-21 |
Day's range | 11.76 - 11.77 |
Contract range | N/A |
Volume | |
Open interest | N/A |
PRINCETON, N.J., October 03, 2024--U.S. FDA Approves Perioperative Treatment of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo...
A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?
Shattuck stock plunges as it discontinues the clinical development of SL-172154 for two blood cancer indications and plans to reduce the workforce by 40%.